[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418185":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":10,"centralContacts":89,"locations":95,"responsibleParty":112,"collaborators":116,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":154,"sex":160,"minAge":10,"maxAge":161,"enrollmentInfo":162,"targetDuration":10,"studyType":165,"phases":10,"briefSummary":166,"conditions":167,"keywords":10,"overallStatus":97,"whyStopped":10,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"Seattle Children's Hospital","OTHER",[8,16,25,31],{"label":9,"type":10,"description":11,"interventionNames":12},"disease modifying anti-rheumatic drug, DMARD",null,"1. Methotrexate 1 mg\u002Fkg (max 25 mg) PO or SQ weekly\n2. Sulfasalazine 30 mg\u002Fkg (max 1000 mg) PO twice daily\n3. Leflunomide 10-20 mg PO daily",[13,14,15],"Drug: Methotrexate","Drug: Sulfasalazine","Drug: Leflunomide",{"label":17,"type":10,"description":18,"interventionNames":19},"tumor necrosis factor inhibitor, TNFi","1. Adalimumab (subcutaneous) 10-40 mg SQ every other week\n2. Etanercept (subcutaneous) 12.5-50 mg SQ every week\n3. Infliximab (intravenous) 10 mg\u002Fkg (max 1000 mg) i.v. at week 0,2, 6 then every 4 weeks\n4. Golimumab (subcutaneous or intravenous) 2 mg\u002Fkg (max 200 mg) at every 4 weeks",[20,21,22,23,24],"Drug: Etanercept","Drug: Adalimumab","Drug: Certolizumab","Drug: Infliximab","Drug: Golimumab",{"label":26,"type":10,"description":27,"interventionNames":28},"bisphosphonate","1. Pamidronate 1 mg\u002Fkg (max 90 mg) (intravenous)\\*:\n\n   Option 1: every month Option 2: 3 consecutive days every 3 months\n2. Zoledronic acid 0.0125-0.05 mg\u002Fkg (max 4mg) (intravenous): every 3-6 months. \\* Both options may use lower dose of 0.5 mg\u002Fkg at the initiation of the treatment. All options allow concurrent use of NSAIDs.",[29,30],"Drug: Pamidronate","Drug: Zoledronic acid",{"label":32,"type":10,"description":33,"interventionNames":34},"non-steroidal anti-inflammatory drugs","1. Naproxen 10 mg\u002Fkg (max 500 mg) PO twice daily\n2. Indomethacin 1 mg\u002Fkg (max daily dose 150 mg) PO twice or three times daily\n3. Meloxicam 0.1-0.3 mg\u002Fkg (max 15 mg) PO daily\n4. Piroxicam 10-20 mg PO daily\n5. Ibuprofen 10 mg\u002Fkg (max 800 mg) PO 3-4 times daily",[35],"Drug: NSAID",[37,42,47,52,57,60,65,70,75,80,85],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"DRUG","Methotrexate","second-line treatment for children with CNO\u002FCRMO after failure to respond to NSAIDs",[9],{"type":38,"name":43,"description":40,"armGroupLabels":44,"otherNames":45},"Sulfasalazine",[9],[46],"Azulfidine",{"type":38,"name":48,"description":40,"armGroupLabels":49,"otherNames":50},"Leflunomide",[9],[51],"areva",{"type":38,"name":53,"description":40,"armGroupLabels":54,"otherNames":55},"Pamidronate",[26],[56],"Aredia",{"type":38,"name":58,"description":40,"armGroupLabels":59,"otherNames":10},"Zoledronic acid",[26],{"type":38,"name":61,"description":40,"armGroupLabels":62,"otherNames":63},"Etanercept",[17],[64],"enbrel",{"type":38,"name":66,"description":40,"armGroupLabels":67,"otherNames":68},"Adalimumab",[17],[69],"humira",{"type":38,"name":71,"description":40,"armGroupLabels":72,"otherNames":73},"Certolizumab",[17],[74],"cimzia",{"type":38,"name":76,"description":40,"armGroupLabels":77,"otherNames":78},"Infliximab",[17],[79],"remicade, inflectra",{"type":38,"name":81,"description":40,"armGroupLabels":82,"otherNames":83},"Golimumab",[17],[84],"simponi",{"type":38,"name":86,"description":87,"armGroupLabels":88,"otherNames":10},"NSAID","first-line treatment",[32],[90],{"name":91,"role":92,"phone":93,"phoneExt":10,"email":94},"Yongdong (Dan) Zhao, MD, PhD","CONTACT","206-987-2000","crmoresearch@seattlechildrens.org",[96],{"facility":5,"status":97,"city":98,"state":99,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":108,"contacts":109},"RECRUITING","Seattle","Washington","98105","United States","US",{"type":104,"coordinates":105},"Point",[106,107],-122.33207,47.60621,{"lat":107,"lon":106},[110],{"name":111,"role":92,"phone":93,"phoneExt":10,"email":94},"Joshua Scheck, BS",{"type":113,"investigatorFullName":114,"investigatorTitle":115,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yongdong (Dan) Zhao","Principle Investigator",[117,119,121,124,126,128,130,132,134,136,138,140,142,144,146,148,150],{"name":118,"class":6},"Boston Children's Hospital, Boston, MA, USA",{"name":120,"class":6},"Hospital for Special Surgery, New York",{"name":122,"class":123},"Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA","UNKNOWN",{"name":125,"class":123},"Riley Children's Hospital, Indianapolis, IN, USA",{"name":127,"class":123},"University of North Carolina, Chapel Hill, NC, USA",{"name":129,"class":6},"Royal Children's Hospital",{"name":131,"class":6},"Hacettepe University",{"name":133,"class":123},"Bambino Gesù Children's Hospital, Rome, Italy",{"name":135,"class":123},"University of British Columbia, Vancouver, BC, Canada",{"name":137,"class":123},"Meyer Children's Hospital, Florence, Italy",{"name":139,"class":6},"Mansoura University",{"name":141,"class":123},"University of Utah, Salt Lake City, UT, USA",{"name":143,"class":123},"University of Iowa Carver College of Medicine, Iowa City, IA, USA",{"name":145,"class":6},"Ann & Robert H Lurie Children's Hospital of Chicago",{"name":147,"class":123},"Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia",{"name":149,"class":6},"Alder Hey Children's NHS Foundation Trust",{"name":151,"class":6},"University of Calgary","100418185","chronic-nonbacterial-osteomyelitis-international-registry-100418185",false,"NCT04725422","CHronic Nonbacterial Osteomyelitis International Registry","CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)","CHOIR","Inclusion Criteria:\n\n* \\- Age at enrollment is equal to or younger than 21 years of age\n* Presence of bone edema on STIR or T2 fat saturation sequence on MRI within 12 weeks of enrollment\n* Whole body imaging evaluation (either WB MRI or bone scintigraphy)\n* Bone biopsy to exclude infection or malignancy unless bone lesions follow typical distribution or there is IBD, psoriasis, or palmar plantar pustulosis\n\nExclusion Criteria:\n\n* \\- History of or current malignancy\n* Current infectious osteomyelitis\n* Contraindication to the selected treatment agent","ALL","21 Years",{"count":163,"type":164},2000,"ESTIMATED","OBSERVATIONAL","The objective of the study is to establish a prospective disease registry for chronic recurrent multifocal osteomyelitis (CRMO)\u002Fchronic nonbacterial osteomyelitis (CNO) in order to investigate the natural history of the disease and the responses of patients to different clinical managements over 10 years.",[168,169],"Chronic Nonbacterial Osteomyelitis","Chronic Recurrent Multifocal Osteomyelitis","2024-07-27",{"date":172,"type":173},"2024-07-30","ACTUAL",{"date":175,"type":173},"2018-08-01",{"date":177,"type":164},"2050-08",{"name":5,"class":6},1]